相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。ANOMALOUS FUNCTIONAL LANGUAGE LATERALIZATION IN SEMANTIC VARIANT PPA
Zachary A. Miller et al.
NEUROLOGY (2015)
Individual and Composite Study Endpoints: Separating the Wheat from the Chaff
Robert Goldberg et al.
AMERICAN JOURNAL OF MEDICINE (2014)
Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis
Sandra Meyer-Moock et al.
BMC NEUROLOGY (2014)
Multiple Sclerosis Outcome Assessments Consortium: Genesis and initial project plan
Richard A. Rudick et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
Composite end points to assess delay of disability progression by MS treatments
J. Zhang et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
Addressing the regulatory and scientific challenges in multiple sclerosis - a statement from the EU regulators
Pavel Balabanov et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
Defining the clinical course of multiple sclerosis The 2013 revisions
Fred D. Lublin et al.
NEUROLOGY (2014)
Clinically meaningful performance benchmarks in MS Timed 25-Foot Walk and the real world
Myla D. Goldman et al.
NEUROLOGY (2013)
Impact of Natalizumab on Ambulatory Improvement in Secondary Progressive and Disabled Relapsing-Remitting Multiple Sclerosis
Diego Cadavid et al.
PLOS ONE (2013)
Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects
Jeffrey A. Cohen et al.
LANCET NEUROLOGY (2012)
Comparison of Disease Activity in SPMS and PPMS in the Context of Multicenter Clinical Trials
Rotem Orbach et al.
PLOS ONE (2012)
Challenges to clinical trials in multiple sclerosis: outcome measures in the era of disease-modifying drugs
Megan Hyland et al.
CURRENT OPINION IN NEUROLOGY (2011)
A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS
M. S. Freedman et al.
NEUROLOGY (2011)
Progression on the Multiple Sclerosis Functional Composite in multiple sclerosis: what is the optimal cut-off for the three components?
L. V. A. E. Bosma et al.
MULTIPLE SCLEROSIS JOURNAL (2010)
The search for responsive clinical endpoints in primary progressive multiple sclerosis
L. V. A. E. Bosma et al.
MULTIPLE SCLEROSIS JOURNAL (2009)
Assessing disability progression with the Multiple Sclerosis Functional Composite
R. A. Rudick et al.
MULTIPLE SCLEROSIS JOURNAL (2009)
Disability as an outcome in MS clinical trials
G. C. Ebers et al.
NEUROLOGY (2008)
Is a 20% change in MSFC components clinically meaningful?
Lisa Contelloe et al.
MULTIPLE SCLEROSIS (2007)
Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis
J. J. Kragt et al.
MULTIPLE SCLEROSIS JOURNAL (2006)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Responsiveness of the Multiple Sclerosis Impairment Scale in comparison with the Expanded Disability Status Scale
M Ravnborg et al.
MULTIPLE SCLEROSIS JOURNAL (2005)
The patient's perception of a (reliable) change in the Multiple Sclerosis Functional Composite
ELJ Hoogervorst et al.
MULTIPLE SCLEROSIS (2004)
The Multiple Sclerosis Functional Composite: a new clinical outcome measure for multiple sclerosis
RA Rudick et al.
MULTIPLE SCLEROSIS (2002)
Benefit of interferon β-1a on MSFC progression in secondary progressive MS
JA Cohen et al.
NEUROLOGY (2002)
Quantitative functional measures in MS: What is a reliable change?
SR Schwid et al.
NEUROLOGY (2002)
Relapses and progression of disability in multiple sclerosis.
C Confavreux et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
分享论文
